EU/3/15/1565
Table of contents
About
On 9 October 2015, orphan designation (EU/3/15/1565) was granted by the European Commission to PBS Regulatory Consulting Group Limited, United Kingdom, for 2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide for the treatment of hepatocellular carcinoma.
The sponsorship was transferred to Southwood Research Ltd in March 2020.
This medicine is now known as namodenoson.
Key facts
Active substance |
2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (namodenoson)
|
Disease / condition |
Treatment of hepatocellular carcinoma
|
Date of first decision |
09/10/2015
|
Outcome |
Positive
|
EU designation number |
EU/3/15/1565
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
Southwood Research Ltd
Gustav Mahlerplein 2
1082 MA Amsterdam
Noord-Holland
The Netherlands
Tel. +31 2079 97362
E-mail: tom@southwoodresearch.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.